|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01801 INNOVENT BIO
Nominal 
35.950 -1.250 (-3.360%) | 2024/06 - Interim RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 147,810 | (1,918,804) | (2,024,843) | (307,688) |
| Net Cash from / (used in) Investing Activities | -- | (998,662) | (1,435,185) | (2,698,148) | (5,184,588) |
| Net Cash from / (used in) Financing Activities | -- | 2,587,257 | 2,892,082 | 5,003,361 | 4,912,121 |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 1,736,405 | (461,907) | 280,370 | (580,155) |
| Cash & Cash Equivalents at beginning of period | -- | 1,016,165 | 1,359,408 | 1,276,178 | 2,425,806 |
| Effect of Foreign Exchange Rate Changes | -- | (6,877) | 118,664 | (197,140) | (569,473) |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 2,745,693 | 1,016,165 | 1,359,408 | 1,276,178 |
| Remarks: | Real time quote last updated: 18/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -392,620 |
| %Change | 182.158% |
| EPS / (LPS) | RMB -0.240 |
| NBV Per Share (¥) | RMB 7.631 |